Archives
-
NP-40 Lysis Buffer for FPR2/ALX Assays
2026-10-01
Discover how NP-40 Lysis Buffer can support native-complex and phosphoprotein analysis in FPR2/ALX neuroimmune studies. This article translates mechanistic findings on microglia, NK cells, and SYK-AKT signaling into practical sample-preparation and assay-design decisions.
-
O-propargyl-puromycin: Reading B-Cell Translation
2026-10-01
O-propargyl-puromycin (OPP) converts nascent protein synthesis into a measurable chemical signal. This article explains how to interpret OPP data in the Pcbp1–mitochondrial axis of B-cell biology without confusing global translation with antibody-specific output.
-
Novobiocin Sodium: DNA Replication Workflow
2026-09-30
Novobiocin Sodium is an aminocoumarin antibiotic for temporally controlled studies of bacterial DNA replication, protoplast enlargement, membrane synthesis, and vacuole formation. This guide converts reference findings into practical assay workflows, controls, and troubleshooting strategies for cell cycle, DNA damage, and antibiotic resistance research.
-
GDF11, Smad2/3, and Antioxidant Aging Biology
2026-09-30
This 2022 Biogerontology study used yeast-surface-displayed recombinant GDF11 to examine whether oral delivery can delay aging-associated changes in male mice. Its central contribution is linking GDF11 intake to stronger antioxidant defenses, lower oxidative damage, and delayed senescence biomarkers through canonical Smad2/3 signaling.
-
HATU for Peptide Coupling and Inhibitor Synthesis
2026-09-29
HATU combines rapid carboxylic acid activation with practical control over amide and ester formation, making it useful for peptide synthesis chemistry and medicinal chemistry libraries. This guide connects bench-scale coupling decisions with the structure-guided IRAP inhibitor work reported in the reference study, while keeping synthetic performance separate from biological validation.
-
CAF–ANGPTL4–IQGAP1 Axis in Prostate Cancer
2026-09-29
This study identifies a paracrine CAF–ANGPTL4–IQGAP1 pathway that reprograms prostate cancer cells toward mitochondrial biogenesis and oxidative phosphorylation, reducing chemotherapy sensitivity. Its integrated proteomic, metabolomic, biochemical, and pharmacologic approach highlights tumor–stroma signaling as a potential target for improving docetaxel response.
-
Cycloheximide in Hypoxia–Apoptosis Research
2026-09-28
Cycloheximide is a protein biosynthesis inhibitor that can clarify how translational capacity shapes hypoxia-associated apoptosis. This article connects ribosomal elongation blockade with HIF-1α–Septin4 biology and shows how to interpret protein turnover and caspase readouts without overstating causality.
-
HRP Goat Anti-Mouse IgG (H+L) Antibody
2026-09-28
This HRP-labeled secondary antibody detects mouse IgG primary antibodies in workflows such as Western blotting, ELISA, IHC, and ICC, where enzyme-based signal development is required. It is not a substitute for a primary antibody and is not intended to detect non-mouse primary antibodies or to serve as a live-cell sorting reagent.
-
Tricine-SDS-PAGE Gel Preparation Kit Workflow
2026-09-27
The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit is designed to improve separation of low-molecular-weight proteins and peptides, particularly in the 1–10 kDa range. It is intended for research electrophoresis workflows, including appropriately configured denaturing or non-denaturing applications, and is not for diagnostic or medical use.
-
2,2,2-Trichloroethanol in Translational Protein Analysis
2026-09-26
Explore how 2,2,2-Trichloroethanol can support protein-level checks in research workflows—and why those checks answer different questions from dopamine-transporter PET. A critical reading of a Parkinson’s cell-therapy study shows how to connect molecular biology research with in vivo evidence without conflating the methods.
-
Phosphatase Inhibitor Cocktail 1 for Signaling
2026-09-25
Preserve phosphorylation during cell and tissue lysis with a DMSO-based cocktail formulated to inhibit alkaline and serine/threonine phosphatases. See how to integrate it into Western blot, co-immunoprecipitation, and phosphoproteomic workflows—and how to interpret those assays alongside transcriptional findings in HPV16-positive cancer research.
-
Phosphatase Inhibitor Cocktail 1 for CRC Signaling
2026-09-25
Preserve phosphoprotein readouts when testing colorectal cancer signaling, from p-AKT and p-mTOR Western blots to phosphoproteomic workflows. This practical guide shows how to add a 100X inhibitor stock to lysis steps, control DMSO, and troubleshoot results without implying that the featured CRC study used this reagent.
-
α-Bungarotoxin for Nicotinic Receptor Blockade
2026-09-24
Use α-Bungarotoxin to test whether α7 nicotinic acetylcholine receptor signaling is required for a cellular response—not merely associated with it. A recent placental ischemia study illustrates how antagonist reversal can connect cholinergic signaling to necroptosis, inflammation, and trophoblast behavior, while offering a practical framework for controlled follow-up experiments.
-
SNS-032: Interpreting CDK Inhibition Across Cell Systems
2026-09-24
SNS-032 (BMS-387032) inhibits CDK2, CDK7, and CDK9, but its effects must be interpreted across phosphorylation, protein abundance, and cell-state readouts. This article connects cancer-research workflows with a 2026 SARS-CoV-2 host-factor study while clearly distinguishing its CDK9 inhibitor from SNS-032.
-
PDGF-BB Assays for Vascular Remodeling Research
2026-09-23
Use murine recombinant PDGF-BB as a defined mitogenic stimulus to benchmark smooth muscle cell proliferation alongside hypoxia-driven pulmonary vascular remodeling. This workflow pairs practical dose-finding and handling guidance with clear limits: PDGF-BB is an experimental comparator, not a substitute for the ALDOB–DRP1 mechanism described in the reference study.